vs
Beam Therapeutics Inc.（BEAM）与合众银行（OSBC）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是合众银行的1.2倍（$114.1M vs $93.8M），Beam Therapeutics Inc.净利率更高（214.1% vs 27.3%，领先186.8%）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
合众银行是一家总部位于美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构。截至2025年，它是美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构，主营银行、投资、抵押等金融服务。
BEAM vs OSBC — 直观对比
营收规模更大
BEAM
是对方的1.2倍
$93.8M
净利率更高
BEAM
高出186.8%
27.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $93.8M |
| 净利润 | $244.3M | $25.6M |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | — |
| 净利率 | 214.1% | 27.3% |
| 营收同比 | 279.5% | — |
| 净利润同比 | 370.4% | 159.2% |
| 每股收益（稀释后） | $2.53 | $0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMOSBC
| Q1 26 | — | $93.8M | ||
| Q4 25 | $114.1M | $95.2M | ||
| Q3 25 | — | $95.9M | ||
| Q2 25 | — | $75.1M | ||
| Q1 25 | — | $73.1M | ||
| Q4 24 | — | $73.2M | ||
| Q3 24 | — | $71.2M | ||
| Q2 24 | — | $70.8M |
净利润BEAMOSBC
| Q1 26 | — | $25.6M | ||
| Q4 25 | $244.3M | — | ||
| Q3 25 | — | $9.9M | ||
| Q2 25 | — | $21.8M | ||
| Q1 25 | — | $19.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $23.0M | ||
| Q2 24 | — | $21.9M |
营业利润率BEAMOSBC
| Q1 26 | — | — | ||
| Q4 25 | -15.3% | 41.2% | ||
| Q3 25 | — | 13.6% | ||
| Q2 25 | — | 38.9% | ||
| Q1 25 | — | 35.8% | ||
| Q4 24 | — | 34.7% | ||
| Q3 24 | — | 41.9% | ||
| Q2 24 | — | 41.2% |
净利率BEAMOSBC
| Q1 26 | — | 27.3% | ||
| Q4 25 | 214.1% | — | ||
| Q3 25 | — | 10.3% | ||
| Q2 25 | — | 29.0% | ||
| Q1 25 | — | 27.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 32.3% | ||
| Q2 24 | — | 30.9% |
每股收益（稀释后）BEAMOSBC
| Q1 26 | — | $0.48 | ||
| Q4 25 | $2.53 | $0.53 | ||
| Q3 25 | — | $0.18 | ||
| Q2 25 | — | $0.48 | ||
| Q1 25 | — | $0.43 | ||
| Q4 24 | — | $0.42 | ||
| Q3 24 | — | $0.50 | ||
| Q2 24 | — | $0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $115.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $893.3M |
| 总资产 | $1.5B | $6.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BEAMOSBC
| Q1 26 | — | $115.7M | ||
| Q4 25 | $1.2B | $124.0M | ||
| Q3 25 | — | $116.5M | ||
| Q2 25 | — | $141.8M | ||
| Q1 25 | — | $256.1M | ||
| Q4 24 | — | $99.3M | ||
| Q3 24 | — | $115.8M | ||
| Q2 24 | — | $120.9M |
股东权益BEAMOSBC
| Q1 26 | — | $893.3M | ||
| Q4 25 | $1.2B | $896.8M | ||
| Q3 25 | — | $866.7M | ||
| Q2 25 | — | $718.6M | ||
| Q1 25 | — | $694.5M | ||
| Q4 24 | — | $671.0M | ||
| Q3 24 | — | $661.4M | ||
| Q2 24 | — | $619.3M |
总资产BEAMOSBC
| Q1 26 | — | $6.8B | ||
| Q4 25 | $1.5B | $6.9B | ||
| Q3 25 | — | $7.0B | ||
| Q2 25 | — | $5.7B | ||
| Q1 25 | — | $5.7B | ||
| Q4 24 | — | $5.6B | ||
| Q3 24 | — | $5.7B | ||
| Q2 24 | — | $5.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | — |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | — |
| 自由现金流率自由现金流/营收 | -76.3% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BEAMOSBC
| Q1 26 | — | — | ||
| Q4 25 | $-83.3M | $122.3M | ||
| Q3 25 | — | $35.9M | ||
| Q2 25 | — | $24.2M | ||
| Q1 25 | — | $17.8M | ||
| Q4 24 | — | $131.5M | ||
| Q3 24 | — | $48.5M | ||
| Q2 24 | — | $11.6M |
自由现金流BEAMOSBC
| Q1 26 | — | — | ||
| Q4 25 | $-87.0M | $117.8M | ||
| Q3 25 | — | $34.7M | ||
| Q2 25 | — | $23.5M | ||
| Q1 25 | — | $16.2M | ||
| Q4 24 | — | $120.7M | ||
| Q3 24 | — | $46.2M | ||
| Q2 24 | — | $8.7M |
自由现金流率BEAMOSBC
| Q1 26 | — | — | ||
| Q4 25 | -76.3% | 123.7% | ||
| Q3 25 | — | 36.2% | ||
| Q2 25 | — | 31.2% | ||
| Q1 25 | — | 22.2% | ||
| Q4 24 | — | 165.0% | ||
| Q3 24 | — | 64.9% | ||
| Q2 24 | — | 12.3% |
资本支出强度BEAMOSBC
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | 4.7% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 4.2% |
现金转化率BEAMOSBC
| Q1 26 | — | — | ||
| Q4 25 | -0.34× | — | ||
| Q3 25 | — | 3.64× | ||
| Q2 25 | — | 1.11× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.11× | ||
| Q2 24 | — | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
OSBC
| Net Interest Income | $81.1M | 87% |
| Noninterest Income | $12.6M | 13% |
